Progesterone 5β-reductase genes of the Brassicaceae family as function-associated molecular markers

This study aimed to define progesterone 5β-reductases (P5βR, EC 1.3.99.6, enone 1,4-reductases) as function-associated molecular markers at the plant family level. Therefore cDNAs were isolated from 25 Brassicaceae species, including two species, Erysimum crepidifolium and Draba aizoides, known to produce cardiac glycosides. The sequences were used in a molecular phylogeny study. The cladogram created is congruent to the existing molecular analyses. Recombinant His-tagged forms of the P5βR cDNAs from Aethionema grandiflorum, Draba aizoides, Nasturtium officinale, Raphanus sativus and Sisymbrium officinale were expressed in E. coli. Enone 1,4-reductase activity was demonstrated in vitro using progesterone and 2-cyclohexen-1-one as substrates. Evidence is provided that functional P5βRs are ubiquitous in the Brassicaceae. The recombinant P5βR enzymes showed different substrate preferences towards progesterone and 2-cyclohexen-1-one. Sequence comparison of the catalytic pocket of the P5βR enzymes and homology modelling using Digitalis lanata P5βR (PDB ID: 2V6G) as template highlighted the importance of the hydrophobicity of the binding pocket for substrate discrimination. It is concluded that P5βR genes or P5βR proteins can be used as valuable function-associated molecular markers to infer taxonomic relationship and evolutionary diversification from a metabolic/catalytic perspective.

Study of electronic and magnetic properties and related x-ray absorption spectroscopy of ultrathin Co films on BaTiO3

We present a first-principles study of electronic and magnetic properties of thin Co films on a BaTiO3(0 0 1) single crystal. The crystalline structure of 1-3 monolayer thick Co films was determined and served as input for calculations of the electronic and magnetic properties of the films. The estimation of exchange constants indicates that the Co films are ferromagnetic with a high critical temperature, which depends on the film thickness and the interface geometry. In addition, we calculated x-ray absorption spectra, related magnetic circular dichroism (XMCD) and linear dichroism (XLD) of the Co L 2, 3 edges as a function of Co film thickness and ferroelectric polarization of BaTiO3. We found characteristic features, which depend strongly on the magnetic properties and the structure of the film. While there is only a weak dependence of XMCD spectra on the ferroelectric polarization, the XLD of the films is much more sensitive to the polarization switching, which could possibly be observed experimentally.

Importance of early absolute lymphocyte count after allogeneic stem cell transplantation: a retrospective study

INTRODUCTION

Early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation (HSCT) is related to the prevention of serious infections and the clearing of residual tumor cells.

METHODS

We analyzed the absolute lymphocyte count at 20 (D+20) and 30 (D+30) days after HSCT in 100 patients with malignant hematologic diseases and correlated with the risk of transplant-related mortality, overall survival (OS), disease-free survival (DFS), nonrelapsed mortality (NRM), and risk of infection.

RESULTS

Patients presenting with lymphocyte counts of <300 × 103/μL on D+30 have a 3.76 times greater risk of death in <100 days. Over a medium follow-up of 20 months OS, DFS, and NRM were similar between the groups.

CONCLUSION

In our group of patients delayed lymphocyte recovery after HSCT was a predictor of early death post-HSCT.

OCORRÊNCIA DE ANTICORPOS CONTRA O HERPESVÍRUS EQUINO E VIRUS DA ARTERITE EQUINA EM REBANHOS EQUINOS DO ESTADO DO RIO DE JANEIRO

<title>Resumo</title><p>A infecção pelo herpesvírus equino (EHV) e o vírus da arterite equina (EAV) tem sido associada a perdas econômicas importantes para a equideocultura em nível mundial. Estudos sorológicos têm demonstrado a circulação destes agentes no Brasil. O presente trabalho teve como objetivo principal estudar a ocorrência de anticorpos específicos contra o EAV e EHV em cavalos oriundos de diferentes regiões do estado do Rio de Janeiro. Para este propósito, foram coletadas amostras de soro de 581 animais não vacinados e de 44 éguas provenientes de um plantel vacinado regularmente contra a rinopneunonite equina. Todas as amostras foram submetidas ao teste de soroneutralização para a pesquisa de anticorpos específicos contra cada um dos vírus. Os resultados demonstraram 29,6% (172/581) de animais soropositivos para o EHV (títulos entre 2 e ≥ 256) e 0,79% (05/630) para o EAV (títulos entre 2 e 4.096). Considerando a sorologia positiva em animais não imunizados, os achados demonstram a indução de anticorpos específicos após exposição natural aos respectivos vírus, indicando uma possível circulação desses agentes nos rebanhos analisados.</p>

Next Step toward Optimization of GRP Receptor Avidities: Determination of the Minimal Distance between BBN(7-14) Units in Peptide Homodimers

As the gastrin releasing peptide receptor (GRPR) is overexpressed on several tumor types, it represents a promising target for the specific in vivo imaging of these tumors using positron emission tomography (PET). We were able to show that PESIN-based peptide multimers can result in substantially higher GRPR avidities, highly advantageous in vivo pharmacokinetics and tumor imaging properties compared to the respective monomers. However, the minimal distance between the peptidic binders, resulting in the lowest possible system entropy while enabling a concomitant GRPR binding and thus optimized receptor avidities, has not been determined so far. Thus, we aimed here to identify the minimal distance between two GRPR-binding peptides in order to provide the basis for the development of highly avid GRPR-specific PET imaging agents. We therefore synthesized dimers of the GRPR-binding bombesin analogue BBN(7-14) on a dendritic scaffold, exhibiting different distances between both peptide binders. The homodimers were further modified with the chelator NODAGA, radiolabeled with (68)Ga, and evaluated in vitro regarding their GRPR avidity. We found that the most potent of the newly developed radioligands exhibits GRPR avidity twice as high as the most potent reference compound known so far, and that a minimal distance of 62 bond lengths between both peptidic binders within the homodimer can result in concomitant peptide binding and optimal GRPR avidities. These findings answer the question as to what molecular design should be chosen when aiming at the development of highly avid homobivalent peptidic ligands addressing the GRPR.

EFEITO DO EXTRATO AQUOSO DE PRÓPOLIS MARROM SOBRE A PRODUÇÃO DE IFN-γ APÓS IMUNIZAÇÃO CONTRA PARVOVÍRUS CANINO (CPV) E CORONAVÍRUS CANINO (CCoV)

O objetivo deste estudo foi avaliar a capacidade adjuvante imunoestimulatória do extrato aquoso de própolis marrom (EAPM) quando associado a uma vacina contra parvovírus canino (CPV) e coronavírus canino (CCoV), com relação à produção de IFN-γ. Camundongos foram vacinados com CPV e CCoV (3,0x106 TCDI50) em associação ou não com 400 μg/dose de EAPM. Trinta dias após a terceira dose foi realizado cultivo de esplenócitos para mensuração dos níveis de expressão de mRNA para IFN-γ nos animais imunizados. O aumento nos níveis de expressão de mRNA para IFN-γ para CCoV nos esplenócitos dos camundongos inoculados com a vacina contendo 400 μg/dose de EAPM foi evidenciado por RT-PCR, demonstrando a capacidade da própolis em estimular a resposta imune celular contra os antígenos desse vírus. Ao contrário, os níveis de IFN-γ para CPV não sofreram influência da presença do EAPM.

HLA class II peptide tetramers vs allergen-induced proliferation for identification of allergen-specific CD4 T cells

BACKGROUND

Fluorescence-labeled MHC class II/peptide tetramer complexes are considered as optimal tools to characterize allergen-specific CD4(+) T cells, but this technique is restricted to frequently expressed HLA class II molecules and knowledge of immunodominant epitopes. In contrast, allergen-stimulated proliferation assessed by CFSE dilution is less sophisticated and widely applicable. The major mugwort allergen, Art v 1, contains only one single, immunodominant, HLA-DR1-restricted epitope (Art v 125-36 ). Thus, essentially all Art v 1-reactive cells should be identified by a HLA-DRB1*01:01/Art v 119-36 tetramer.

METHODS

We compared specificity and sensitivity of tetramer(+) and allergen-induced proliferating (CFSE(lo) ) CD4(+) T cells by flow cytometry.

RESULTS

The frequency of tetramer(+) CD4(+) T cells determined ex vivo in PBMC of mugwort-allergic individuals ranged from 0 to 0.029%. After 2-3 weeks of in vitro expansion, sufficient tetramer(+) T cells for phenotyping were detected in 83% of Art v 125-36 -reactive T-cell lines (TCL) from mugwort-allergic individuals, but not in TCL from healthy individuals. The tetramers defined bona fide Th2 cells. Notably, Art v 125-36 -reactive TCL depleted of tetramer(+) T cells still reacted to the peptide, and only 44% of Art v 125-36 -specific T-cell clones were detected by the tetramer. CFSE(lo) CD4(+) T cells contained only 0.3-10.7% of tetramer(+) T cells and very low proportions of Th2 cells.

CONCLUSION

Allergen-specific T cells can be identified by HLA class II tetramers with high specificity, but unexpected low sensitivity. In contrast, allergen-stimulated CFSE(lo) CD4(+) T cells contain extremely high fractions of bystander cells. Therefore, for T-cell monitoring, either method should be interpreted with caution.

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

Antiviral activity of a Bacillus sp. P34 peptide against pathogenic viruses of domestic animals

P34 is an antimicrobial peptide produced by a Bacillus sp. strain isolated from the intestinal contents of a fish in the Brazilian Amazon basin with reported antibacterial activity. The aim of this work was to evaluate the peptide P34 for its in vitro antiviral properties against canine adenovirus type 2 (CAV-2), canine coronavirus (CCoV), canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), equine arteritis virus (EAV), equine influenza virus (EIV), feline calicivirus (FCV) and feline herpesvirus type 1 (FHV-1). The results showed that the peptide P34 exhibited antiviral activity against EAV and FHV-1. The peptide P34 inhibited the replication of EAV by 99.9% and FHV-1 by 94.4%. Virucidal activity was detected only against EAV. When P34 and EAV were incubated for 6 h at 37 °C the viral titer reduced from 10(4.5) TCID50 to 10(2.75) TCID50, showing a percent of inhibition of 98.6%. In conclusion, our results demonstrated that P34 inhibited EAV and FHV-1 replication in infected cell cultures and it showed virucidal activity against EAV. Since there is documented resistance to the current drugs used against herpesviruses and there is no treatment for equine viral arteritis, it is advisable to search for new antiviral compounds to overcome these infections.

Neonatal abstinence syndrome in European and North American neonates: differences in clinical characteristics derived from a prospective randomized trial

BACKGROUND

Due to the steady increase of substance-dependent pregnant women the neonatal abstinence syndrome has become an increasingly important issue in neonatology. The present study investigates site-specific differences of detailed symptoms and treatment of neonatal abstinence syndrome within the context of an international multicenter clinical trial.

METHODS

Site specific neonatal data analyses from a prospective randomized, double-blind, double-dummy clinical trial (MOTHER study) was performed. A standardized NAS rating and treatment protocol was applied, while non-pharmacological care of NAS symptoms differed across the sites.

RESULTS

Urban US neonates exhibited most neurological symptoms (p<0.001) while in Europe autonomous, respiratory and gastrointestinal symptoms were found significantly more often compared to urban and/or rural US (p<0.05). Methadone produced significantly greater scores than buprenorphine in neurological, behavioural and respiratory symptoms regardless of the sites (ps<0.05). NAS treatment rates in all site clusters were similar for methadone-exposed neonates, while in Europe significantly more buprenorphine-exposed neonates were treated (p=0.001) than in US site clusters. Urban US neonates had significantly higher NAS scores (p<0.01) compared to rural US and European neonates, and needed significantly higher morphine doses (p<0.05) with longer treatment duration. Birth weight, length and head circumference did not differ significantly among the site clusters, but APGAR scores were significantly higher in European (p<0.01) neonates.

CONCLUSION

In addition to intrauterine medication exposure other aspects such as different addiction severity of the mothers, different treatment modalities including rooming-in as well as the frequency of NAS ratings may be influencing the course of NAS.

Denis RD, Stahlman J, Stamen R, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Staude A, Stavina P, Steele G, Steinbach P, Steinberg P, Stekl I, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoerig K, Stoicea G, Stonjek S, Strachota P, Stradling AR, Straessner A, Strandberg J, Strandberg S, Strandlie A, Strang M, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Strong JA, Stroynowski R, Stugu B, Stumer I, Stupak J, Sturm P, Styles NA, Soh DA, Su D, Subramania HS, Subramaniam R, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Suzuki Y, Svatos M, Swedish S, Sykora I, Sykora T, Sánchez J, Ta D, Tackmann K, Taffard A, Tafirout R, Taiblum N, Takahashi Y, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev A, Tamsett MC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanasijczuk AJ, Tani K, Tannoury N, Tapprogge S, Tardif D, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tayalati Y, Taylor C, Taylor FE, Taylor GN, Taylor W, Teinturier M, Teischinger FA, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Terada S, Terashi K, Terron J, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thoma S, Thomas JP, Thompson EN, Thompson PD, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thong WM, Thun RP, Tian F, Tibbetts MJ, Tic T, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tiouchichine E, Tipton P, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tomoto M, Tompkins L, Toms K, Tonoyan A, Topfel C, Topilin ND, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Triplett N, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, True P, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiakiris M, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsung JW, Tsuno S, Tsybychev D, Tua A, Tudorache A, Tudorache V, Tuggle JM, Turala M, Turecek D, Turk Cakir I, Turlay E, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Tzanakos G, Uchida K, Ueda I, Ueno R, Ugland M, Uhlenbrock M, Uhrmacher M, Ukegawa F, Unal G, Undrus A, Unel G, Unno Y, Urbaniec D, Urquijo P, Usai G, Uslenghi M, Vacavant L, Vacek V, Vachon B, Vahsen S, Valenta J, Valentinetti S, Valero A, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, Van Berg R, Van Der Deijl PC, van der Geer R, van der Graaf H, Van Der Leeuw R, van der Poel E, van der Ster D, van Eldik N, van Gemmeren P, van Vulpen I, Vanadia M, Vandelli W, Vaniachine A, Vankov P, Vannucci F, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vassilakopoulos VI, Vazeille F, Vazquez Schroeder T, Vegni G, Veillet JJ, Veloso F, Veness R, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinek E, Vinogradov VB, Virchaux M, Virzi J, Vitells O, Viti M, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel A, Vokac P, Volpi G, Volpi M, Volpini G, von der Schmitt H, von Radziewski H, von Toerne E, Vorobel V, Vorwerk V, Vos M, Voss R, Voss TT, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Wagner W, Wagner P, Wahlen H, Wahrmund S, Wakabayashi J, Walch S, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Walsh B, Wang C, Wang H, Wang H, Wang J, Wang J, Wang R, Wang SM, Wang T, Warburton A, Ward CP, Wardrope DR, Warsinsky M, Washbrook A, Wasicki C, Watanabe I, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh AT, Waugh BM, Weber MS, Webster JS, Weidberg AR, Weigell P, Weingarten J, Weiser C, Wells PS, Wenaus T, Wendland D, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Werth M, Wessels M, Wetter J, Weydert C, Whalen K, White A, White MJ, White S, Whitehead SR, Whiteson D, Whittington D, Wicek F, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilhelm I, Wilkens HG, Will JZ, Williams E, Williams HH, Willis W, Willocq S, Wilson JA, Wilson MG, Wilson A, Wingerter-Seez I, Winkelmann S, Winklmeier F, Wittgen M, Wollstadt SJ, Wolter MW, Wolters H, Wong WC, Wooden G, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wraight K, Wright M, Wrona B, Wu SL, Wu X, Wu Y, Wulf E, Wynne BM, Xella S, Xiao M, Xie S, Xu C, Xu D, Xu L, Yabsley B, Yacoob S, Yamada M, Yamaguchi H, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamazaki T, Yamazaki Y, Yan Z, Yang H, Yang UK, Yang Y, Yang Z, Yanush S, Yao L, Yao Y, Yasu Y, Ybeles Smit GV, Ye J, Ye S, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJ, Youssef S, Yu D, Yu J, Yu J, Yuan L, Yurkewicz A, Zabinski B, Zaidan R, Zaitsev AM, Zajacova Z, Zanello L, Zanzi D, Zaytsev A, Zeitnitz C, Zeman M, Zemla A, Zendler C, Zenin O, Ženiš T, Zinonos Z, Zerwas D, Zevi della Porta G, Zhang D, Zhang H, Zhang J, Zhang X, Zhang Z, Zhao L, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou N, Zhou Y, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhuravlov V, Zibell A, Zieminska D, Zimin NI, Zimmermann R, Zimmermann S, Zimmermann S, Ziolkowski M, Zitoun R, Živković L, Zmouchko VV, Zobernig G, Zoccoli A, zur Nedden M, Zutshi V, Zwalinski L. The differential production cross section of the [Formula: see text](1020) meson in [Formula: see text] = 7 TeV [Formula: see text] collisions measured with the ATLAS detector

A measurement is presented of the [Formula: see text] production cross section at [Formula: see text] = 7 TeV using [Formula: see text] collision data corresponding to an integrated luminosity of 383 [Formula: see text], collected with the ATLAS experiment at the LHC. Selection of [Formula: see text](1020) mesons is based on the identification of charged kaons by their energy loss in the pixel detector. The differential cross section is measured as a function of the transverse momentum, [Formula: see text], and rapidity, [Formula: see text], of the [Formula: see text](1020) meson in the fiducial region 500 [Formula: see text] 1200 MeV, [Formula: see text] 0.8, kaon [Formula: see text] 230 MeV and kaon momentum [Formula: see text] 800 MeV. The integrated [Formula: see text]-meson production cross section in this fiducial range is measured to be [Formula: see text] = 570 [Formula: see text] 8 (stat) [Formula: see text] 66 (syst) [Formula: see text] 20 (lumi) [Formula: see text].

Speicherung des labilen Silaethens Me2Si=C(SiMe3)2 mit N-Trimethylsilyl-benzophenonimin Ph2C=NSiMe3 / Storing of the Labile Silaethene Me2Si=C(SiMe3)2 with N-Trimethylsilyl-benzophenoneimine Ph2C=NSiMe3

N-Trimethylsilyl-benzophenoneimine Ph2C=NSiMe3 is able to “store" the silaethene Me2Si = C(SiMe3)2 (1). produced from Me2SiF-CLi(SiMe3)2, under formation of a [2+4]- and [2+2]-cycloadduct (2, 3), respectively. Above 60 °C (above 120 °C) 2 or 3 by the way of 1 transform into a 1:5 mixture of 2 and 3 (into a 1:1 mixture of the dimer of 1 and the insertion product of 1 into the SiN-bond of Ph2C=NSiMe3). In the presence of 2,3-dimethyl-1.3-butadiene (dmb), 2 or 3 form by way of the reaction of the intermediate 1 with dmb a [2 + 4]-cycloadduct (75%) and an ene reaction product (25%). The rate constants of the first order decomposition of 2 or 3 in the presence of dmb (80 °C. solvents like Et2O, Q6H6 are in the order of 2x10-4s-1 (τ1/2ca. 1 h) and 3x10- 5s-1 (τ1/2 ca. 6 h). respectively.